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LETTERS TO THE EDITORS
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We read with great interest Uguz’s1 review of pharmacotherapy of obsessive-compulsive disorder (OCD) during pregnancy. Given the relative frequency with which
OCD, as well as other psychiatric disorders, present during pregnancy, establishing evidence-based therapies that
are safe and acceptable is of critical importance.
Within the strengths of this article (e.g., clinical relevance
to a vulnerable population), there was limited mention
of cognitive-behavioral psychotherapeutic interventions
for OCD during pregnancy. This is of particular concern
for two reasons. First, cognitive-behavioral therapy (CBT)
with exposure and response prevention is the single most
effective intervention available for adults with OCD, demonstrating superiority as a monotherapy both to serotonin
reuptake inhibitor (SRI) medications and to other forms of
psychotherapy in terms of response rates and degree of
improvement.2 Based on the strength of this evidence,
CBT is recommended as a first-line intervention for those
with OCD regardless of pregnancy. As an augmentation
approach to SRIs, CBT has demonstrated greater reduction in OCD symptoms than risperidone, which did not
differ from placebo.3 Preliminary efficacy data, similar in
quality to that for SRIs during pregnancy, supports this
approach in working with women in the postpartum period.4
Given the similarity of content, onset, and development patterns of OCD in pregnancy and the postpartum, these
results should be extrapolatable.
Second, the side effect profile of many medications,
especially antipsychotics (i.e., weight gain, increased
appetite), makes their use a last resort in this population,
and some women may find pharmacotherapy an undesirable treatment approach. More concerning are the effects
of SRIs on fetal development as discussed by Uguz,1
including increasing evidence of the role of fluoxetine and
paroxetine in fetal defects and high risk of poor neonatal
adaptation syndrome, whereas for other SRIs, the data on
this possible linkage are few and inconsistent. The effects

of antipsychotics on the developing fetus remain unexplored and not adequately evaluated at this time to recommend use. As reviewed above, cognitive-behavioral
interventions have demonstrated sound efficacy across
numerous studies for reducing obsessive-compulsive
symptoms in adults, with a negligible side effect profile
and no theoretical reason why it might impact the developing fetus. Thus, clinicians should base treatment decisions
on a complete assessment of all available therapies;
when data are limited for OCD during pregnancy, extrapolating from the treatment literature more broadly may
be appropriate to achieve the most effective and safe
treatment of the affected individual and developing fetus,
since pregnancy does not appear to be related to poor
response to CBT.5
In short, caution should be used in incorporating conclusions from this report into clinical practice, given the
strength of the current literature supporting pharmacotherapy during pregnancy (relative to CBT) and the
associated side effect profile. Behavioral interventions are
an important treatment component for this population,
and the psychiatric care of pregnant women should be
multidisciplinary, involving physicians, psychologists, and
other allied health professionals. Collectively, the limited
available data on pharmacological and behavioral interventions highlight the need for further clinical trials
investigating potentially viable therapies that are safe,
effective, and acceptable.
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F. Psychological treatment of obsessive-compulsive disorder: a metaanalysis. Clin Psychol Rev. 2008;28:1310-25.
3 Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill
S, et al. A randomized, controlled trial of cognitive-behavioral therapy
for augmenting pharmacotherapy in obsessive-compulsive disorder.
Am J Psychiatry. 2008;165:621-30.
4 Christian LM, Storch EA. Cognitive behavioral treatment of postpartum onset obsessive compulsive disorder with aggressive obsessions. Clin Case Stud. 2009;8:72-83.
5 Abramowitz JS, Schwartz SA, Moore KM, Luenzmann KR. Obsessivecompulsive symptoms in pregnancy and the puerperium: a review of the
literature. J Anxiety Disord. 2003;17:461-78.

